News
🇪🇺 EuropeLatest pharmaceutical news, drug approvals, and EMA regulatory updates
Latest News
EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams
The European Medicines Agency (EMA) has announced its latest drug approvals, including new active substances and indications. This update provides critical intelligence for pharmaceutical business development teams and investors tracking market catalysts.
CHMP Approves New Medicines: Key Decisions and Implications for the Pharmaceutical Industry
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recently made critical decisions regarding drug approvals. This article breaks down the latest outcomes, their significance for the pharmaceutical sector, and future considerations.
FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension
The FDA has approved AstraZeneca's baxdrostat (Baxfendy), the first-in-class aldosterone synthase inhibitor, for adults with uncontrolled hypertension. This landmark approval offers a new therapeutic option for patients with difficult-to-treat hypertension.
SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB
SERB Pharmaceuticals has entered into an agreement to acquire the European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma AB. This strategic acquisition aims to expand SERB's rare disease portfolio.
Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients
The FDA has granted Priority Review to Datroway for the treatment of metastatic triple-negative breast cancer (TNBC) in patients not eligible for immunotherapy. This designation marks a significant step for AstraZeneca and offers a potential new therapeutic avenue for a challenging cancer subtype.
X4 Pharmaceuticals' Mavorixafor Receives EMA Approval Recommendation for WHIM Syndrome
X4 Pharmaceuticals has secured a significant milestone as its drug, mavorixafor, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of WHIM syndrome in the European Union. This follows the drug's prior approval in the U.S.
Italy's Clinical Research Landscape: Strengths, Weaknesses, and Strategic Implications
Italy holds a strong position in European clinical research volume, ranking fourth overall. However, significant delays in patient enrollment are hindering its competitiveness and attractiveness for global trials.
EMA Initiates Implementation of New EU Pharmaceutical Legislation: What Pharma Needs to Know
The European Medicines Agency (EMA) has begun the critical phase of implementing the new EU pharmaceutical legislation, establishing a dedicated gateway for updates and timelines. This proactive approach signals the start of significant regulatory shifts impacting drug development and market access across the EU.
Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment
Regeneron Pharmaceuticals' stock shows resilience despite a recent analyst price target reduction and ongoing European Medicines Agency (EMA) review of an eye drug. The market appears to be absorbing these developments without significant share price volatility.
Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option
The European Medicines Agency (EMA) has accepted Teva Pharmaceuticals and Medincell's marketing authorization application for their once-monthly olanzapine long-acting injectable (LAI) for the treatment of schizophrenia in adults. This regulatory milestone signifies a potential new adherence-focused treatment option for patients in Europe.
ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address
The ASCO 2026 annual meeting presented a subdued landscape for European pharmaceutical giants like AstraZeneca and Roche, highlighting areas where both companies need to intensify their strategic efforts. Despite a quiet conference, significant market dynamics are at play for these oncology leaders.
ESMO 2025: Key Advances in Non-Muscle-Invasive Bladder Cancer Shape Future Oncology Strategies
The ESMO 2025 congress presented critical advancements in non-muscle-invasive bladder cancer (NMIBC), notably featuring results from the POTOMAC and ALBAN trials. These findings are poised to significantly influence treatment paradigms and commercial strategies within the oncology sector.
Datroway and Trodelvy Vie for First-Line TNBC Dominance Amidst Evolving Treatment Landscape
Datroway and Trodelvy, two TROP2-targeting antibody-drug conjugates, are poised to enter a head-to-head competition in the first-line treatment of triple-negative breast cancer (TNBC). This evolving landscape presents significant strategic considerations for pharmaceutical business development and investment.
Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress
Idorsia's investigational vaccine, IDOR-1134-2831, targeting Clostridioides difficile infection (C. diff), has demonstrated continued positive clinical trajectory in early-stage trials. The vaccine aims to prevent recurrent C. diff infections, a significant unmet medical need.
Ascentage Pharma's 17 Clinical Advances at EHA 2026
Ascentage Pharma is set to present 17 clinical advances at the 2026 European Hematology Association Congress, marking a pivotal moment for the company. This presentation could influence investment decisions and competitive strategies in the hematology sector.
Bio/Pharma Outlook 2026: Regulatory Updates and Implications
As we approach 2026, significant regulatory updates are set to reshape the bio/pharma landscape. This article outlines key developments and their implications for stakeholders.
FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights
The FDA has delayed the review of AstraZeneca's breast cancer drug, raising questions about the future of the drug and its market impact. Here's what you need to know.
2026 Italy Drug & Medical Device Litigation Report: Key Insights
This report highlights critical updates on drug and medical device litigation laws in Italy for 2026, focusing on clinical trials and their implications.
Rethinking QA/QC at The Future of Bio/Pharmaceutical Analysis 2026
Day one of The Future of Bio/Pharmaceutical Analysis 2026 highlighted innovative approaches to QA/QC. This article summarizes key insights and implications for the industry.
International School of Clinical Oncology Annual Congress 2026: Key Insights
The International School of Clinical Oncology Annual Congress 2026 is set to unveil groundbreaking advancements in oncology. This article outlines key insights and implications for the pharmaceutical industry.